PARP1
Poly [ADP-ribose] polymerase 1
As of the edition of 20 October 2026, PARP1 (poly [ADP-ribose] polymerase 1, UniProt P09874) has 11 drugs tested at it and 16 companies on the list, 3 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P09874
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 106
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Hormones; Skin and connective tissue; Digestive system; Lungs and airways; Blood and lymph
- Registered trials of its drugs
- 940
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 4 |
| Stopped | 3 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Olaparib | Marketed | Phase 4 | Ends 2028 |
| Niraparib | Marketed | Phase 4 | Ends 2031 |
| Talazoparib | Marketed | Phase 3 | Ends 2031 |
| Veliparib | Stopped | Phase 3 | none listed |
| Rucaparib | Marketed | Phase 3 | Ends 2031 |
| Pamiparib | Stopped | Phase 3 | none listed |
| Saruparib | Active | Phase 3 | none listed |
| Senaparib | Active | Phase 2 | none listed |
| 2X-121 | Active | Phase 2 | none listed |
| Amelparib | Active | Phase 2 | none listed |
| E-7016 | Stopped | Phase 2 | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 6 |
| Engaged | 4 |
| Undetermined | 3 |
| Total on the list | 16 |
The other 13 companies at PARP1
In the product16 companies in all; 13 are not named here, and no score is.
See the 16 companies at PARP1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.